NTLA icon

Intellia Therapeutics

8.87 USD
+0.67
8.17%
At close Apr 30, 4:00 PM EDT
After hours
8.89
+0.02
0.23%
1 day
8.17%
5 days
9.78%
1 month
24.75%
3 months
-15.60%
6 months
-38.10%
Year to date
-27.41%
1 year
-58.55%
5 years
-34.15%
10 years
-59.86%
 

About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Employees: 598

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 8 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

91% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 66

43% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $11.5M

31% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 49

5.71% more ownership

Funds ownership: 91.75% [Q3] → 97.45% (+5.71%) [Q4]

4% more funds holding

Funds holding: 280 [Q3] → 290 (+10) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

40% less capital invested

Capital invested by funds: $1.91B [Q3] → $1.16B (-$756M) [Q4]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$13
47%
upside
Avg. target
$34
283%
upside
High target
$68
667%
upside

8 analyst ratings

positive
75%
neutral
25%
negative
0%
Wolfe Research
Andy Chen
53% 1-year accuracy
8 / 15 met price target
137%upside
$21
Outperform
Upgraded
21 Apr 2025
HC Wainwright & Co.
Mitchell Kapoor
31% 1-year accuracy
58 / 188 met price target
238%upside
$30
Buy
Initiated
5 Mar 2025
Truist Securities
Joon Lee
48% 1-year accuracy
20 / 42 met price target
464%upside
$50
Buy
Maintained
4 Mar 2025
Barclays
Gena Wang
14% 1-year accuracy
4 / 29 met price target
193%upside
$26
Overweight
Maintained
28 Feb 2025
Citigroup
David Lebowitz
37% 1-year accuracy
7 / 19 met price target
58%upside
$14
Neutral
Maintained
28 Feb 2025

Financial journalist opinion

Based on 144 articles about NTLA published over the past 30 days

Positive
The Motley Fool
8 hours ago
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood's investing style is bouncing back into fancy. The co-founder, CEO, and investment manager of Ark Invest is winning again.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Positive
Zacks Investment Research
1 day ago
Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 392.8% in Intellia Therapeutics (NTLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet
Neutral
PRNewsWire
1 week ago
Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation
SAN DIEGO , April 23, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of those NASDAQ: NTLA shares also have certain options and contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation
Neutral
GlobeNewsWire
2 weeks ago
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLA
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLA
Neutral
Accesswire
2 weeks ago
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=143015&wire=1 or contact Joseph E. Levi, Esq.
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Neutral
PRNewsWire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA
NEW YORK , April 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA
Neutral
GlobeNewsWire
2 weeks ago
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQ: NTLA) and certain of its officers.
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Neutral
Accesswire
2 weeks ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Lawsuit - NTLA
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=142988&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Lawsuit - NTLA
Neutral
Accesswire
2 weeks ago
NTLA DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ:NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NTLA DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA
Neutral
Business Wire
2 weeks ago
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Charts implemented using Lightweight Charts™